Skip to main content

Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip

Objective

The quest for new medical drugs demands reliable, ultrasensitive and fast techniques to identify, refine and test small volumes of candidates for clinical trials. The efficacy of pharmaceuticals depends to a large extent on their chiral composition, and thus enantiomeric purity and selectivity is an important issue for the development of new drugs and to test their biotoxicity. TwistedNano addresses this need with a new generation of integrated nanophotonic devices enabling ultrasensitive chiroptical spectroscopy of sub-nanolitre volumes, revolutionizing at-source the sensing technological toolbox for drug discovery and nanomedicine.

Because of governmental regulations, agencies require pharmaceutical manufacturers to investigate systematically most of drug enantiomers to determine their safety/efficacy. Thus, the development of fast, compact and accurate chiral sensing on a chip is one of the current primary targets of the nanomedicine industry, constituting a growing market that is already exceeding 100 billion Euros. TwistedNano will result in a photonics-enabled chiral sensing technology that integrates vectorial structured light fields with almost arbitrary control onto a microfluidic chip, providing groundbreaking advantages compared to current instrumentation: (i) remote/distributed analysis, (ii) reduced sample consumption, (iii) cost reduction, (iv) parallelization, (v) increased diagnostic speed and sensitivity.

Key elements developed for optofluidic integration include photonic crystal fibers, photonic nanostructures, and metasurfaces operating in close synergy with cutting-edge chiroptical spectroscopic techniques. In the mid-term, TwistedNano will not only lay the foundations of a new lab-on-chip chiral sensing technology revolutionizing drug discovery, theranostics and nanomedicine, but also open a plethora of disruptive applications such as characterization of minute amounts of viruses and macromolecules in general.

Coordinator

UNIVERSITA DEGLI STUDI DELL'AQUILA
Net EU contribution
€ 385 485,00
Address
Piazza Santa Margherita 2
67100 L Aquila
Italy

See on map

Region
Sud Abruzzo L’Aquila
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (6)

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
Net EU contribution
€ 755 347,50
Address
Hofgartenstrasse 8
80539 Munchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Non-EU contribution
€ 0,00
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
Net EU contribution
€ 644 282,50
Address
Rue Michel Ange 3
75794 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,00
DOMPE FARMACEUTICI SPA
Italy
Net EU contribution
€ 242 267,50
Address
Via S Martino Della Battaglia 12
20122 Milano

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Italy
Net EU contribution
€ 373 750,00
Address
Via Morego 30
16163 Genova

See on map

Region
Nord-Ovest Liguria Genova
Activity type
Research Organisations
Non-EU contribution
€ 0,00
FUNDACIO INSTITUT DE CIENCIES FOTONIQUES
Spain
Net EU contribution
€ 712 105,00
Address
Avinguda Carl Friedrich Gauss 3
08860 Castelldefels

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Non-EU contribution
€ 0,00
FORESEE BIOSYSTEMS SRL
Italy
Net EU contribution
€ 84 687,50
Address
Via Venti Settembre 33/10
16121 Genova

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Nord-Ovest Liguria Genova
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00